Track topics on Twitter Track topics that are important to you
Edison Investment Research - Pharmaceutical & healthcare - Therapix Biosciences: Therapix is investigating the potential of new formulations of cannabinoids to address underserved diseases of the brain. It recently listed on NASDAQ in the US 2.3m ADS (worth $13.8m). The lead clinical program, THX-TS01, is currently in Phase II trials testing its potential for treating Tourette’s in adults and THX-ULD01 is scheduled to begin Phase I trials for the treatment of mild cognitive impairment (MCI) in mid-2017. Both programs should qualify for a 505(b)(2) pathway to streamline approval. We arrive at an initial valuation of $38.4m or $10.97 per ADS.
Original Article: Therapix Biosciences (TRPX) - Tackling neurology with cannabinoidsNEXT ARTICLE
Health care (or healthcare) is the diagnosis, treatment, and prevention of disease, illness, injury, and other physical and mental impairments in humans. Health care is delivered by practitioners in medicine, chiropractic, dentistry, nursing, pharmacy, a...
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...